ANK2

Across TCGA pan-cancer cohorts, ANK2 Mutation is linked to patient survival in 13 of 34 cancer types, making it a survival-associated ANK2 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ANK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

ACC, ESCA, and THCA are the cancer types where ANK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.624	<.001	27	view →
ESCA	DFS	Median	All	0.178	0.543	<.001	21	view →
THCA	DFS	Median	III,IV	0.100	0.927	<.001	18	view →
READ	OS	Median	IV	0.111	0.893	<.001	14	view →
UCEC	DFS	Median	All	0.739	0.623	.016	14	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
SCLC	DFS	Median	II,III,IV	0.292	0.608	.011	12	view →
HNSC	OS	Median	All	0.253	0.615	.004	9	view →
LGG	OS	Median	All	0.219	0.889	<.001	6	view →
PRAD	DFS	Median	All	0.142	0.778	<.001	6	view →
SKCM	DFS	Median	All	0.486	0.782	<.001	5	view →
COAD	OS	Median	III,IV	1.000	0.508	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

ANK2–ACC (DFS)

Open the ACC breakdown →